Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 2/2018

01-02-2018 | Letter to the editor

How to report adherence to treatment as clinically relevant data—making a case of CML and TKI

Author: Lucas Miyake Okumura

Published in: Supportive Care in Cancer | Issue 2/2018

Login to get access

Excerpt

Adherence comes from the Latin word “adhaerere”, and implies to “remain constant”, to “keep close” or to “maintain” [1]. When this concept is brought to therapeutics, such as patients with chronic myeloid leukemia (CML) using tyrosine kinase inhibitors (TKI), the persistence of an individual to adhering to treatment is somehow simplified to self-referred and non-validated questionnaires [2]. …
Literature
1.
2.
Breccia M, Efficace F, Alimena G (2012) Adherence to treatment is a complex and multifaceted issue that can substantially alter the outcome of chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Leuk Res 36:804–805CrossRefPubMed
3.
Moulin SM, Eutrópio FJ, Souza JO et al (2017) The role of clinical pharmacists in treatment adherence: fast impact in suppression of chronic myeloid leukemia development and symptoms. Support Care Cancer 25:951–955CrossRefPubMed
4.
Vrijens B, Goetghebeur E, de Klerk E et al (2005) Modelling the association between adherence and viral load in HIV-infected patients. Stat Med 24:2719–2731CrossRefPubMed
5.
Okumura LM, Antunes VD, Aguiar KS et al (2015) Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment. Pharm Pract (Granada) 13:559CrossRef
6.
Guilhot J, Preudhomme C, Mahon FX et al (2015) Analyzing molecular response in chronic myeloid leukemia clinical trials: pitfalls and golden rules. Cancer 121:490–497CrossRefPubMed
7.
Morisky DE, Ang A, Krousel-Wood M et al (2008) Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 10:348–354CrossRef
8.
Gater A, Heron L, Abetz-Webb L et al (2012) Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leuk Res 36:817–825CrossRefPubMed
9.
10.
Ganesan P, Sagar TG, Dubashi B (2011) Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 86:471–474CrossRefPubMed
Metadata
Title
How to report adherence to treatment as clinically relevant data—making a case of CML and TKI
Author
Lucas Miyake Okumura
Publication date
01-02-2018
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 2/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-017-3809-2

Other articles of this Issue 2/2018

Supportive Care in Cancer 2/2018 Go to the issue

Review Article

Effects of acupuncture on cancer-related fatigue: a meta-analysis

Commentary

Longitudinal assessment of the impact of adapted physical activity on upper limb disability and quality of life in breast cancer survivors from an Italian cohort

Original Article

Acute impact of home parenteral nutrition in patients with late-stage cancer on family caregivers: preliminary data

Original Article

Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS

Original Article

Comparison of group vs self-directed music interventions to reduce chemotherapy-related distress and cognitive appraisal: an exploratory study

Original Article

Caregiving and mutuality among long-term colorectal cancer survivors with ostomies: qualitative study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits